Heidelberg Pharma AG
Clinical-stage biopharma developing Amanitin-based ADCs for targeted cancer therapies.
HPHA | F
Overview
Corporate Details
- ISIN(s):
- DE000A11QVV0
- LEI:
- 391200E09XYBYITR1W32
- Country:
- Germany
- Address:
- Gregor-Mendel-Str. 22, 68526 Ladenburg
- Sector:
- Manufacturing
Description
Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2009-01-09 00:10 |
WILEX and UCB agree on a strategic allianceWILEX AG:
|
English | 4.8 KB | ||
| 2008-10-13 08:25 |
WILEX releases 9-month Financial Report 2008: Significant progress in developme…
|
English | 7.8 KB | ||
| 2008-10-13 00:00 |
Q3 Report 2007/2008
|
German | 704.8 KB | ||
| 2008-09-16 14:39 | German | 2.5 KB | |||
| 2008-08-11 09:00 |
WILEX AG starts patient recruitment in Phase II breast cancer trial with its uP…
|
English | 7.7 KB | ||
| 2008-07-24 09:26 |
WILEX AG: Patient recruitment in Phase II trial with MESUPRON (WX-671) in pancr…
|
English | 6.7 KB | ||
| 2008-07-17 00:00 |
Q2 Report 2007/2008
|
English | 1.1 MB | ||
| 2008-07-14 08:55 |
WILEX reports successful first half year 2008
|
English | 8.2 KB | ||
| 2008-07-03 14:11 |
WILEX AG: Phase III ARISER study with RENCAREX: patient recruitment successfull…
|
English | 6.4 KB | ||
| 2008-06-06 07:55 |
WILEX and IBA enter into worldwide marketing, distribution and sales agreement …
|
English | 8.4 KB | ||
| 2008-06-06 07:34 |
WILEX and IBA enter into worldwide marketing, distribution and sales agreement …
|
English | 4.6 KB | ||
| 2008-05-19 11:51 |
WILEX AG: Patient recruitment started in Phase III registration trial with CA9-…
|
English | 6.2 KB | ||
| 2008-04-10 09:12 |
WILEX reports successful first quarter 2008
|
English | 6.8 KB | ||
| 2008-04-10 00:00 |
Q1 Report 2007/2008
|
German | 681.3 KB | ||
| 2008-02-20 08:28 |
WILEX AG reports a successful financial year 2007 positive outlook for 2008
|
English | 8.5 KB |
Automate Your Workflow. Get a real-time feed of all Heidelberg Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Heidelberg Pharma AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Heidelberg Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-31 | Pahl, Prof. Dr. Andreas | Board | Other | None | N/A |
| 2023-12-18 | Pahl, Prof. Dr. Andreas | Board | Buy | None | 10,130.00 EUR |
| 2022-10-13 | 4H invest GmbH | Close relation | Other | None | 993,666.24 EUR |
| 2022-10-13 | Bohlini invest GmbH | Close relation | Other | None | 964,061.56 EUR |
| 2022-10-13 | MH-LT-Investments GmbH | Close relation | Other | None | 506,241.96 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 13,088.40 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 4,895.60 EUR |
| 2022-09-07 | Plate, Achim | Board | Buy | None | 30,869.92 EUR |
| 2022-09-06 | Kudlek, Dr. Birgit | Supervisory board | Other | None | 7,496.16 EUR |
| 2022-03-22 | 4H invest GmbH | Close relation | Other | None | N/A |
Peer Companies
